UniQure's gene therapy continues to slow Huntington's progression after four years. But the magnitude of the benefit waned ...

In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear ...

Qure’s Ifezuntirgene slowed disease progression by 80% on a measure combining movement, thinking and daily function.

Qure N.V. (NASDAQ:QURE) shares fell 64% on Tuesday after the gene therapy developer reported updated 48-month data for ...

For decades, so many families have watched loved ones suffer from Huntington's disease, a neurodegenerative condition that progressively worsens over time. But now, there is finally a light at the end ...

Add Yahoo as a preferred source to see more of our stories on Google. Huntington’s disease is a progressive brain disorder caused by a defective gene (Alamy/PA) Scientists have slowed the progression ...

Analysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting ...

UniQure filed for accelerated FDA approval early this month. (uniQure) uniQure’s Huntington’s disease gene therapy has failed ...

uniQure said AMT-130 continued to slow Huntington’s disease in ongoing early- and mid-stage studies after four years.

Huntington's disease (HD) has long been impossible to cure, but new research is finally giving fresh hope. HD is a progressive, hereditary brain disease that affects movement, cognition and emotions.

Sept 29 () - UniQure said ‌on ‌Tuesday its Huntington's ​treatment showed 44% slowing of ‌disease progression, ⁠but did not ⁠reach statistical significance ​in ​an ​ongoing early-to-mid-stage ...

TFC showed a 61% slowing of disease progression, with a nominal p-value of 0.008. uniQure also conducted a post-hoc sensitivity analysis using an earlier external control dataset. The analysis showed ...